Bildkälla: Stockfoto

Immunicum: Our comment on the Q3 2021 report - Redeye

Redeye comments on Immunicum’s Q3 2021 report, which came without any surprises. Looking forward, we anticipate important clinical trial data from the company’s ADVANCE II and ILIAD phase Ib trials during the fourth quarter. Further, the company plans to announce its updated clinical development strategy during Q1 2022.

Redeye comments on Immunicum’s Q3 2021 report, which came without any surprises. Looking forward, we anticipate important clinical trial data from the company’s ADVANCE II and ILIAD phase Ib trials during the fourth quarter. Further, the company plans to announce its updated clinical development strategy during Q1 2022.
Börsvärldens nyhetsbrev
ANNONSER